InMed Pharmaceuticals is making strides in Alzheimer’s research with its development of a cannabinoid-based compound that aims to protect and rejuvenate brain neurons.

During Benzinga’s virtual event on Thursday, InMed president and CEO Eric A. Adams shared detailed insights into the company’s research and its potential implications for Alzheimer’s treatment.

Neuroprotective Effects and Beyond

InMed’s research focuses on a specific cannabinoid compound that has demonstrated promising neuroprotective effects. This compound not only helps prevent neuron death but also assists in reducing disease-related neuron degeneration.

The team at InMed has observed that the compound aids in the regrowth of neuron connections, which are crucial for cognitive functions.

In addition to its neuroprotective capabilities, the compound has shown effectiveness in decreasing neuroinflammation, a critical factor in the pathology of dementia, says Adams.

"We are decreasing neuroinflammation and helping the neurons regrow," he explained. These findings suggest that the compound could potentially reverse some of the damage caused by Alzheimer’s disease, offering hope for better outcomes for patients.

A Multifaceted Process

InMed’s approach to Alzheimer’s treatment sets it apart from traditional methods that primarily target amyloid beta reduction. While their compound also reduces amyloid beta, the focus is improving overall neuron health.

Adams noted, "Most of the focus has been on amyloid beta reduction, but we think improving the health of the neurons is more important."

Interestingly, the compound operates through multiple pathways, including the cannabinoid receptor and PPAR pathways, the latter being significant due to its connection to diabetes.

He added, "There’s always been a link between diabetes and Alzheimer’s, and we’re exploring how this compound’s multifactorial approach could lead to better outcomes."

Expert Collaboration

To further their research, InMed has enlisted the expertise of Dr. David G. Morgan, a leading Alzheimer’s expert who recently joined the company’s Scientific Advisory Board.

Dr. Morgan's involvement is helping the team understand their data better and lay out a pathway for future clinical trials.

Adams acknowledged, "We are cannabinoid experts, but not Alzheimer’s experts." Dr. Morgan’s guidance is critical in shaping the company’s strategic approach to advancing their Alzheimer’s program.

InMed’s progress in Alzheimer’s research exemplifies the potential of cannabinoid-based therapies to address complex neurological conditions. As they move forward, the company remains focused on bringing their promising compound through clinical trials and ultimately to the patients who need it most.

Now Read: Could CBD Revolutionize Alzheimer’s Treatment? New Study Explores Its Neuroprotective Properties

Image: Shutterstock